Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice President
“Camille is a strategic thinker who has extensive hands-on experience developing new medicines for rare diseases and has helped build successful development organizations,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “Throughout her career she has been highly regarded as a dedicated, patient-focused clinician and leader, and we are thrilled to welcome Camille to Ultragenyx as we continue to build and advance our pipeline of rare disease therapies.”
“Ultragenyx has a strong commitment and track record of developing new treatments that improve the lives of rare disease patients and I will bring my passion and prior experience to this fulfilling role of bringing important therapies to those suffering from rare genetic diseases,” said Dr. Bedrosian.
During her ten years at Alexion, Dr. Bedrosian provided leadership for the development of drugs and drug candidates including those designed to address devastating rare diseases caused by defects in the complement system including Soliris® (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Prior to Alexion, Dr. Bedrosian spent more than five years as the Chief Medical Officer for
Dr. Bedrosian was an Assistant Professor of Medicine at
About
Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The Company has rapidly built and advanced a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The Company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the Company's website at www.ultragenyx.com.
Contact
Investors & Media
415-475-6876
Source: Ultragenyx Pharmaceutical Inc.